Schrodinger, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Schrodinger, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $207.54M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $216.67M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $180.96M | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | $137.93M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $108.10M | Feb 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $207.54M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $216.67M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $180.96M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $137.93M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $108.10M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $85.54M | Feb 24, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.61M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $132.08M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $140.69M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $101.02M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $65.62M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $63.47M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $49.09M | Feb 24, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($103.27M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($187.12M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $40.72M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($149.19M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($100.39M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($24.46M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($24.57M) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($166.90M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($209.30M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($177.45M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($146.82M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($111.44M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($60.92M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($38.72M) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.14M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $201.79M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $181.77M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $126.37M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $90.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $64.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $39.40M | Feb 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($157.37M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($136.73M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($119.68M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($70.67M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $16.76M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($26.06M) | Feb 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.31M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $13.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $8.01M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $7.17M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $2.54M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.84M | Feb 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $726.16M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $823.23M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $802.96M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $688.59M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $756.49M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $746.26M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $155.27M | Mar 4, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $362.11M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $401.78M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $254.40M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $240.68M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $199.40M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $122.24M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $57.01M | Mar 4, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $421.45M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $548.56M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $447.89M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $557.07M | Feb 26, 2025 |
| FY2021 | Dec 31, 2020 | $624.02M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($93.36M) | Mar 4, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.79M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.79M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $4.79M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $4.79M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Feb 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($628.81M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($525.54M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($338.42M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($379.14M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($229.95M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($129.56M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($105.10M) | Mar 4, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.52M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $147.33M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $155.32M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $90.47M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $120.27M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $202.30M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $25.99M | Mar 4, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 62.98M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 62.16M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 61.83M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 60.71M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 6.12M | Mar 4, 2021 |